N
NRG Therapeutics
Mitochondrial therapeutics for neurodegenerative diseases
About NRG Therapeutics
NRG Therapeutics is a drug discovery company founded in 2018, developing treatments for neurodegenerative disorders like Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS). The company's scientific focus is on restoring mitochondrial function by developing small molecule inhibitors of the mitochondrial permeability transition pore (mPTP). Inhibition of the mPTP has been demonstrated in pre-clinical models to protect neurons, decrease neuroinflammation, and improve survival.
The company was co-founded by Neil D. Miller, Richard Rutter, and Grant Hawthorne. Dr. Miller, the CEO, has an extensive background in drug discovery, including an 18-year career at GlaxoSmithKline where he led teams that developed multiple clinical candidates. The founders and leadership team are composed of professionals with significant experience in biotech and pharmaceuticals, specifically within neuroscience research and development.
NRG Therapeutics operates on a business model centered on the discovery and development of its drug candidates, with a goal of advancing them to clinical trials. Its pipeline includes brain-penetrant, oral small molecule inhibitors. The company's lead development candidate, NRG5051, is a first-in-class mPTP inhibitor with potential applications for Parkinson's and ALS.
The company is privately held and based at the Stevenage Bioscience Catalyst in the UK. It has successfully raised capital through a combination of equity investments and grants. Key investors include Omega Funds, Brandon Capital, and Parkinson's UK's Virtual Biotech program. NRG has also secured significant grant funding from organizations such as The Michael J. Fox Foundation, Innovate UK, and Target ALS. Total funding has reached over $18.4 million across several rounds, including a Series A round and multiple grants.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Feb 2026 | $26M | $330M | Undisclosed | ↗ |
| SERIES BOther financing | Sep 2025 | $66M | $264M | Omega Funds · Brandon Capital Partners · Novartis Venture Fund · British Business Bank | ↗ |
Growth signals
Latest recorded traffic for NRG Therapeutics is 2.2K monthly website visits, up 29.4% over the last three months. NRG Therapeutics's team grew 21.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
NRG Therapeutics in the Cambridge ecosystem
The NRG Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Parkinson's UK
Michael J. Fox Foundation for Parkinson's Research
Target ALS
Series A7 investors entered at this stage
Omega Funds
Brandon Capital Partners
SV Health Investors
Novartis Venture Fund
British Business Bank
M Ventures
Criteria Bio Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NRG Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NRG Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










